Small Molecules

9 May 2013

Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in Stroke

9 May 2013

Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes

8 May 2013

Xcovery Vision Presents VEGFR/PDGFR Oral Inhibitor X-82 Preliminary Data for Wet AMD at ARVO

8 May 2013

Actelion provides update on Phase III GRIPHON study with selexipag in pulmonary arterial hypertension – Study continues

8 May 2013

Celsus Therapeutics Announces Positive Phase II Interim Results for MRX-6 in the Treatment of Contact Dermatitis

7 May 2013

EISAI FILES FOR INDICATION EXPANSION OF ANTICANCER AGENT HALAVEN(R) WITH EUROPEAN MEDICINES AGENCY SEEKS EARLIER-LINE USE IN TREATMENT OF METASTATIC BREAST CANCER

7 May 2013

Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis

7 May 2013

Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation

7 May 2013

Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on “The Lancet Oncology”

7 May 2013

Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer

7 May 2013

PROTEROS AND EISAI ACHIEVE TARGET IN LEAD DISCOVERY PROJECT, DELIVERING KINETICALLY OPTIMIZED LEAD COMPOUNDS

6 May 2013

CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma

6 May 2013

La Jolla Pharmaceutical Company Announces Completion of Phase 1 Portion of GCS-100 Clinical Trial in Chronic Kidney Disease

6 May 2013

Trevi Therapeutics Commences Clinical Study of Nalbuphine ER

6 May 2013

Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450

6 May 2013

Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron Therapy

5 May 2013

ESPERION THERAPEUTICS PRESENTS FULL RESULTS OF PHASE 2 CLINICAL TRIAL SHOWING ITS NOVEL ORAL THERAPY ETC-1002 LOWERED LDL-C BY UP TO 43 PERCENT IN HYPERCHOLESTEROLEMIC PATIENTS WITH TYPE 2 DIABETES

5 May 2013

Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA® (efavirenz) in HIV-1 Infected Pediatric Patients

5 May 2013

FDA Approves Merck’s LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol

2 May 2013

Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation

2 May 2013

Zogenix Reports Positive Top-Line Results From Extended Relday(TM) Phase 1 Clinical Trial

2 May 2013

Positive Phase III combo results from its 2nd Study (aclidinium + formoterol)

2 May 2013

Gilead Reports Interim Data From Phase 2 LONESTAR Study

2 May 2013

AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma

1 May 2013

Seaside Therapeutics to Announce Results from a Phase 2b Clinical Trial of Arbaclofen in Autism Spectrum Disorder at the International Meeting for Autism Research (IMFAR) 2013 Conference

1 May 2013

Titan Pharmaceuticals Receives Complete Response Letter From the FDA for Probuphine New Drug Application

1 May 2013

Raptor Pharmaceutical’s PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis

30 April 2013

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence

30 April 2013

GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer

30 April 2013

Trimel Submits New Drug Application for CompleoTRT(TM) to FDA

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Report Package: “Drug the Undruggable” Technologies

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Her3-Targeted Immunotherapy Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins